A research team funded by the National Institutes of Health has launched a study to assess performance and usability of a smartphone app paired with the Quidel QuickVue At-Home Covid-19 Test, which just received an FDA emergency use authorization for use with a prescription. The home test was supported by NIH through the Rapid Acceleration of Diagnostics (RADx) initiative, which has spurred the development and commercial availability of millions of COVID-19 tests over the past year.
More than 200 participants have already enrolled in the study that involves daily testing for a 2-week period. An app called MyDataHelps, developed by CareEvolution, provides step-by-step instructions for taking the test and important tools such as timers to ensure that the steps of the test are performed at the correct time intervals. Although users can interpret the test result on their own, the app also provides an independent confirmation of the result when the user photographs the test strip with the smartphone camera.
Understanding how individuals interact with these apps and where they find value in them will inform future efforts to advance at-home covid-19 testing.
The antigen test gives results in just 10 minutes using a nasal swab sample that is placed in a test tube followed by addition of a test strip. The visually read, colored lines that appear on the test strip indicate a positive or negative result—similar to a pregnancy test.
As rapid, at-home covid-19 tests like QuickVue become more widely available, companion smartphone apps are expected to play an important role in their successful use. Apps offer great potential to assist individuals with administering tests, tracking symptoms, and interpreting results – ultimately resulting in improved test performance and ease-of-use. In addition to providing valuable guidance, apps can also make it straightforward to report results to public health authorities and health care providers.
These technologies are supported by the National Institute for Biomedical Imaging and Bioengineering (NIBIB), part of the NIH. Quidel intends to apply for an additional EUA from the FDA for sale of this test over the counter, without a prescription.
Read more from NIH.